European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. More: Biosimilar Avastin wins EU approval Source: News
read moreBiogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales. More: Biogen ‘optimistic’ for NHS access to
read moreSanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion. More: Sanofi shells out .6bn on Bioverativ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals